Updates in the Treatment of Multiple Myeloma

Presented by:
Shaji K. Kumar
Search for other papers by Shaji K. Kumar in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

The treatment of multiple myeloma is marked by many recent advances, but for newly diagnosed patients the standard of care for induction remains the combination of a proteasome inhibitor, immunomodulatory drug, and dexamethasone. The role of a 4-drug induction regimen is still being defined, but can be considered for patients with high-risk disease. For patients who are eligible to undergo stem cell transplant, this approach remains the preferred option, but transplant can be delayed until relapse if patients prefer. In those who are not eligible for transplant, based on impressive data with daratumumab/lenalidomide/dexamethasone, this triplet should be considered as initial therapy. In patients with relapsed disease, it is important to switch treatment to new drug classes; for this, multiple combinations can be recommended. Updated guidelines now include new drugs for refractory disease: selinexor and belantamab mafodotin, both listed as “other regimens” in the NCCN Guidelines, can be considered.

Disclosures: Dr. Kumar has disclosed receiving grant/research support from AbbVie, Inc., Amgen Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics, Ltd., Celgene Corporation, Janssen Pharmaceutica Products, LP, Kite Pharma, MedImmune Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Roche Laboratories, Inc., sanofi-aventis U.S., Takeda Pharmaceuticals North America, Inc., and TeneoBio; serving as a scientific advisor for AbbVie, Inc., Amgen Inc., Celgene Corporation, Genentech, Inc., Janssen Pharmaceutica Products, LP, MedImmune Inc., sanofi-aventis U.S., and Takeda Pharmaceuticals North America, Inc.; receiving honoraria from BeiGene; and receiving consulting fees from Cellectar Biosciences, Inc., GeneCentrix, Inc., and Oncopeptides.

Correspondence: Shaji K. Kumar, MD, Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905. Email: kumar.shaji@mayo.edu
  • Collapse
  • Expand
  • 1.

    Kumar SK, Callander NS, Adekola K, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma. Version 4.2021. Accessed March 7, 2021. To view the most recent version, visit NCCN.org

    • PubMed
    • Export Citation
  • 2.

    Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomized, controlled trial. Lancet Oncol 2020;21:13171330.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394:2938.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Kaufman JL, Laubach JP, Sborov D, et al. Daratumumab plus lenalidomide, bortezomib, and dexamethasone in patients with transplant-eligible newly diagnosed multiple myeloma: updated analysis of Griffin after 12 months of maintenance therapy [abstract]. Blood 2020;36(Suppl 1):4546.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017;376:13111320.

  • 6.

    Mateos MV, Cavo M, Bladé J, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma: overall survival in Alcyone [abstract]. Blood 2019;134(Suppl 1):Abstract 859.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Kumar SK, Facon T, Usmani SA, et al. Updated analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with transplant-ineligible newly diagnosed multiple myeloma: the phase 3 Maia study [abstract]. Presented at the 62nd ASH Annual Meeting and Exposition; December 5–8, 2020. Abstract 2276.

    • PubMed
    • Export Citation
  • 8.

    Falcon T, Venner CP, Bahlis N, et al. The phase 3 TOURMALINE-MM2 trial: oral ixazomib, lenalidomide, and dexamethasone (IRd) vs placebo-Rd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) [abstract]. Presented at the 62nd ASH Annual Meeting and Exposition; December 5–8, 2020. Abstract 551.

    • PubMed
    • Export Citation
  • 9.

    Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394:20962107.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Dimopoulos MA, Terpos E, Boccadoro M, et al. Apollo: phase 3 randomized study of subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma [abstract]. Presented at the 62nd ASH Annual Meeting and Exposition; December 58, 2020. Abstract 412.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379:18111822.

  • 12.

    Shah JJ, Stadtmauer EA, Abonour R, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 2015;126:22842290.

  • 13.

    Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020;18;396:186197.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuzimab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): interim analysis of a phase 3, randomized, open-label study [abstract]. Presented at the 62nd ASH Annual Meeting and Exposition; December 5–8, 2020. Abstract 2316.

    • PubMed
    • Export Citation
  • 15.

    Chari A, Vogl DT, Dimopoulos MA, et al. Results of the pivotal STORM study (part 2) in penta-refractory multiple myeloma: deep and durable responses with oral Selinexor plus low dose dexamethasone in patients with penta-refractory multiple myeloma [abstract]. Blood 2018;132(Suppl 1):Abstract 598.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020;396:15631573.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21:207221.

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1889 453 16
PDF Downloads 1298 102 13
EPUB Downloads 0 0 0